A BuiltForAI Property
Live federal data · NADAC weekly · Part D CY24

Fluconazole Efinaconazole

Fluconazole vs Efinaconazole — $234.2M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Azole Antifungal
Fluconazole
Brand: Diflucan
First FDA approval:
Azole Antifungal
Efinaconazole
Brand: JUBLIA
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$0.213Per unit
Per unit
Average NADACAcross all dosage forms and strengths
$0.348Up to $0.511
Generic manufacturersActive ANDA holders — FDA Orange Book
1754 total ANDAs filed
33 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$55.1MFull year
$179.1MFull year
Part D claims (CY24)Total fills, all strengths
5.7M3.5M beneficiaries
154K59K beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$10Per claim, all NDCs
$1,164Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
82Minimal friction
2Minimal friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
0None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
NoneClear
Generic availableFDA Orange Book
Yes17 manufacturers
Yes3 manufacturers